CDC42BPA and breast carcinoma: The recently identified azaindole compounds BDP8900 and BDP9066 shown to have high selectivity for MRCKα and MRCKβ over ROCK1 and ROCK2 in in vitro kinase assays and were found to inhibit MRCK-mediated MLC phosphorylation more potently than ROCK-mediated MLC phosphorylation in a breast cancer cell line.